CU22965A1 - PROCEDURE FOR OBTAINING PULMONARY SURFACTANT - Google Patents

PROCEDURE FOR OBTAINING PULMONARY SURFACTANT

Info

Publication number
CU22965A1
CU22965A1 CU1999187A CU1999187A CU22965A1 CU 22965 A1 CU22965 A1 CU 22965A1 CU 1999187 A CU1999187 A CU 1999187A CU 1999187 A CU1999187 A CU 1999187A CU 22965 A1 CU22965 A1 CU 22965A1
Authority
CU
Cuba
Prior art keywords
surfactant
procedure
pulmonary surfactant
obtaining
obtaining pulmonary
Prior art date
Application number
CU1999187A
Other languages
Spanish (es)
Inventor
Lorenzo Wilma De La Caridad Alfonso
Tapia Dahis De Los Angeles Manzanares
Ramos Gretel Villanueva
Casanas Elaine Diaz
Original Assignee
Ct Nac De Sanidad Agropecuaria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Nac De Sanidad Agropecuaria filed Critical Ct Nac De Sanidad Agropecuaria
Priority to CU1999187A priority Critical patent/CU22965A1/en
Publication of CU22965A1 publication Critical patent/CU22965A1/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

El objeto de la presente invención es un procedimiento para la obtención de surfactante pulmonar natural. El surfactante se obtiene de la lixiviación de pulmones de cerdo triturados a través de un procedimiento de purificación sencillo, reproducible, escalable y económico. Su composición bioquímica se caracteriza por: más de 40% de fosfatidilcolina disaturada, más de un 12% de fosfolípidos aniónicos (fosfatidilinositol y fosfatidilglicerol), más de un 5%de triglicéridos, menos de un 2% de proteínas hidrófobas (SP-B y SP-C) y otros lípidos. Este medicamento tiene probada actividad tensoactiva y seguridad, sin necesidad de incorporar fosfolípidos sintéticos.The object of the present invention is a process for obtaining natural pulmonary surfactant. The surfactant is obtained from the leaching of crushed pork lungs through a simple, reproducible, scalable and economical purification procedure. Its biochemical composition is characterized by: more than 40% of desaturated phosphatidylcholine, more than 12% of anionic phospholipids (phosphatidylinositol and phosphatidylglycerol), more than 5% of triglycerides, less than 2% of hydrophobic proteins (SP-B and SP-C) and other lipids. This medicine has proven surfactant activity and safety, without the need to incorporate synthetic phospholipids.

CU1999187A 1999-11-05 1999-11-05 PROCEDURE FOR OBTAINING PULMONARY SURFACTANT CU22965A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CU1999187A CU22965A1 (en) 1999-11-05 1999-11-05 PROCEDURE FOR OBTAINING PULMONARY SURFACTANT

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1999187A CU22965A1 (en) 1999-11-05 1999-11-05 PROCEDURE FOR OBTAINING PULMONARY SURFACTANT

Publications (1)

Publication Number Publication Date
CU22965A1 true CU22965A1 (en) 2004-06-21

Family

ID=46599471

Family Applications (1)

Application Number Title Priority Date Filing Date
CU1999187A CU22965A1 (en) 1999-11-05 1999-11-05 PROCEDURE FOR OBTAINING PULMONARY SURFACTANT

Country Status (1)

Country Link
CU (1) CU22965A1 (en)

Similar Documents

Publication Publication Date Title
PT81298B (en) METHOD FOR PREPARING PHARMACEUTICAL COMPOSITIONS CONTAINING SYNTHETIC PHOSPHOLIPIDS
WO1999038528A3 (en) Vaccine formulations
Rudrammaji et al. Purification and characterization of three acidic, cytotoxic phospholipases A2 from Indian cobra (Naja naja naja) venom
PE20050400A1 (en) HYDROLYZED FISH PROTEIN
DE69113848D1 (en) Use of phosphatidylglycerol (diC 18:10) for the treatment of obstructive respiratory diseases.
BR0215395A (en) Compounds; process for the preparation of a compound; pharmaceutical composition; and method for the treatment and / or prophylaxis of diseases that are related to blood glucose level.
EP0398666A3 (en) A process for modifying the properties of egg yolk
DE60200895D1 (en) Process for the production of pure phosphatides and their use in cosmetics, in the pharmaceutical field and in the field of food
DE69010294D1 (en) Use of antiprogestomimetics to stimulate ovulation.
CU22965A1 (en) PROCEDURE FOR OBTAINING PULMONARY SURFACTANT
BR9816100A (en) Process for the production of desolated phosphatides
SE9002674L (en) PROCEDURES FOR THE PREPARATION OF HIGHLINE PHOSPHATIDYLINOSITOL
UA26313A (en) MEANS FOR SUBSTITUTION THERAPY DISEASES OF THE RESPIRATORY TRACT, PREVIOUSLY WITH SYDHROME
PT84484B (en) PROCESS FOR THE PREPARATION OF SUBMICHRONIC STABILIZED ZIRCONIUM FROM ZIRCONIUM FLUOROSULPHATE AND CERAMIC MATERIALS THAT CONTAINS IT
Kunimoto et al. Vesicle release from rat red cell ghosts and increased association of cell membrane proteins with cytoskeletons induced by cadmium
AR034853A1 (en) SEQUENCE OF SYNTHETIC NUCLEIC ACID CODIFYING AN ALPHA-GALACTOSIDASE, VECTOR AND CELL THAT UNDERSTAND IT, METHOD TO PRODUCE ALFA-GALACTOSIDASE, METHOD TO PREPARE IT, PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH PREPARATION FOR THIS PREPARATION AND SUITABILITY
WO1986005362A3 (en) Egg substitutes
ATE27822T1 (en) HEXAPEPTIDE, PROCESSES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF.
Suzuki et al. Topological location and biological significance of phospholipids in the membrane of Newcastle disease virus. Hydrolysis of phospholipids in intact virion with pure phospholipases A2, C, and D
Rönkkö et al. Partial characterization of a fraction from bull seminal vesicle fluid that potentiates the bull sperm acrosome reaction in vitro
Cserhati et al. Interactions between proteins, peptides and amino acids. New advances 1986–1989
PT1401871E (en) IMMUNOLOGICAL LIGACATION MOLECULES THAT INHIBIT TO SINCICIAL FUSION OF TROPOBLASTO CELLS
Nikitin et al. Blood plasma lipids, lipoproteins and the cholesterol esterification index of the American mink. Mustela vision
IL92584A (en) Process for separation and concentration of apolipoproteins
MX9206448A (en) NEW N-TRITILE PROTECTED ASPARTIC ACID DERIVATIVES FOR PREPARATION OF NMDA PHOSPHONATE ANTAGONISTS.